Effects of targeting the VEGF and PDGF pathways in diffuse orthotopic glioma models

Journal of Pathology

Volumn 223, Issue 5, 2011, Pages 626-634

  Navis, Anna C ^a   Hamans, Bob C ^a   Claes, An ^a   Heerschap, Arend ^a   Jeuken, Judith W M ^a   Wesseling, Pieter ^a   Leenders, William P J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Angiogenesis; Anti angiogenic therapies; Blood brain barrier; Glioblastoma; Magnetic resonance imaging

Indexed keywords

BEVACIZUMAB; GADOLINIUM PENTETATE; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; SUNITINIB; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DRUG EFFICACY; GENE TARGETING; GLIOMA; HISTOPATHOLOGY; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TUMOR GROWTH; TUMOR LOCALIZATION; TUMOR XENOGRAFT;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; GLIOMA; HUMANS; INDOLES; MAGNETIC RESONANCE IMAGING; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; PIPERIDINES; PYRROLES; QUINAZOLINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79952541441     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2836     Document Type: Article

References (32)

1. Wesseling P, Ruiter DJ, Burger PC Angiogenesis in brain tumors; pathobiological and clinical aspects. J Neurooncol 1997; 32: 253-265. (Pubitemid 27077976)
2. Giese A, Bjerkvig R, Berens ME, et al. Cost of migration: invasion of malignant gliomas and implications for treatment. J Clin Oncol 2003; 21: 1624-1636. (Pubitemid 46594118)
3. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009; 10: 459-466.
4. Verhoeff JJ, van Tellingen O, Claes A, et al. Concerns about antiangiogenic treatment in patients with glioblastoma multiforme. BMC Cancer 2009; 9: 444.
5. Claes A, Gambarota G, Hamans B, et al. Magnetic resonance imaging-based detection of glial brain tumors in mice after antiangiogenic treatment. Int J Cancer 2008; 122: 1981-1986. (Pubitemid 351441186)
6. Herbst RS, O'Neill VJ, Fehrenbacher L, et al. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non-small-cell lung cancer. J Clin Oncol 2007; 25: 4743-4750. (Pubitemid 350086476)
7. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342. (Pubitemid 38702844)
8. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357: 2666-2676.
9. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alpha in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-124. (Pubitemid 46089672)
10. Norden AD, Drappatz J, Wen PY. Antiangiogenic therapy in malignant gliomas. Curr Opin Oncol 2008; 20: 652-661.
11. Wedge SR, Ogilvie DJ, Dukes M, et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 2002; 62: 4645-4655.
12. Claes A, Leenders W. Vessel normalization by VEGF inhibition. A complex story. Cancer Biol Ther 2008; 7: 1014-1016.
13. Claes A, Wesseling P, Jeuken J, et al. Antiangiogenic compounds interfere with chemotherapy of brain tumors due to vessel normalization. Mol Cancer Ther 2008; 7: 71-78.
14. Leenders WP, Kusters B, Verrijp K, et al. Antiangiogenic therapy of cerebral melanoma metastases results in sustained tumor progression via vessel co-option. Clin Cancer Res 2004; 10: 6222-6230. (Pubitemid 39287530)
15. Mathews MS, Linskey ME, Hasso AN, et al. The effect of bevacizumab (Avastin) on neuroimaging of brain metastases. Surg Neurol 2008; 70: 649-652; discussion 653.
16. Bergers G, Song S, Meyer-Morse N, et al. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003; 111: 1287-1295. (Pubitemid 36554699)
17. Batchelor TT, Sorensen AG, di Tomaso E, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007; 11: 83-95. (Pubitemid 46075199)
18. Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003; 9: 327-337. (Pubitemid 36109749)
19. Claes A, Schuuring J, Boots-Sprenger S, et al. Phenotypic and genotypic characterization of orthotopic human glioma models and its relevance for the study of anti-glioma therapy. Brain Pathol 2008; 18: 423-433. (Pubitemid 351782851)
20. Gordon MS, Margolin K, Talpaz M, et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001; 19: 843-850. (Pubitemid 32119100)
21. Roodink I, van der Laak J, Kusters B, et al. Development of the tumor vascular bed in response to hypoxia-induced VEGF-A differs from that in tumors with constitutive VEGF-A expression. Int J Cancer 2006; 119: 2054-2062. (Pubitemid 44423661)
22. Gagner JP, Law M, Fischer I, et al. Angiogenesis in gliomas: imaging and experimental therapeutics. Brain Pathol 2005; 15: 342-363. (Pubitemid 41677433)
23. Bernsen H, Van der Laak J, Kusters B, et al. Gliomatosis cerebri: quantitative proof of vessel recruitment by cooptation instead of angiogenesis. J Neurosurg 2005; 103: 702-706. (Pubitemid 43193878)
24. Leenders WP, Kusters B, de Waal RM. Vessel co-option: how tumors obtain blood supply in the absence of sprouting angiogenesis. Endothelium 2002; 9: 83-87. (Pubitemid 35252016)
25. Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28: 1963-1972.
26. Pope WB, Lai A, Nghiemphu P, et al. MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology 2006; 66: 1258-1260. (Pubitemid 43739717)
27. Ebos JM, Lee CR, Cruz-Munoz W, et al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009; 15: 232-239.
28. Paez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009; 15: 220-231.
29. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nature Rev Cancer 2008; 8: 592-603.
30. Kamoun WS, Ley CD, Farrar CT, et al. Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. J Clin Oncol 2009; 27: 2542-2552.
31. Liang WC, Wu X, Peale FV, et al. Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF. J Biol Chem 2006; 281: 951-961.
32. Hu S, Chen Z, Franke R, et al. Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters. Clin Cancer Res 2009; 15: 6062-6069.